Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Ethical Dilemmas II01:30

Ethical Dilemmas II

Resolving an ethical dilemma in healthcare involves a systematic approach that considers every aspect of the issue, respecting both the patient's needs and values and the healthcare professional's ethical obligations. Here are potential steps to resolve an ethical dilemma:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A lack of clean drinking water is associated with lacking food and experiencing food safety threats in 121 countries across the globe.

Nature food·2026
Same author

Did Financial Incentives Increase 5-11-Year-Olds' COVID-19 Vaccination? Synthetic Control Method.

Journal of public health management and practice : JPHMP·2026
Same author

Why do few Medicare beneficiaries switch their Part D prescription drug plans? Insights from behavioral sciences.

Journal of public health policy·2025
Same author

Enhancing Parenting Using AI: Exploratory Hackathon.

JMIR formative research·2025
Same author

Evaluating adherence to patient registration paperwork guidelines: a mystery shopper study in English primary care.

BMJ open·2025
Same author

Preparing for cognitive behavioural therapy: a Delphi exercise to develop a consensus curriculum.

BMJ open·2025

Related Experiment Videos

Medicare Part D Beneficiaries' Experiences with Making Complex Insurance Plan Choices: A Qualitative Interview Study.

Wändi Bruine de Bruin1, Nathan Hodson2, Lila Rabinovich1

  • 1University of Southern California, Los Angeles, CA, USA.

MDM Policy & Practice
|May 14, 2026
PubMed
Summary

Medicare beneficiaries use various strategies for choosing drug plans, but these methods have mixed success. Understanding these decision-making behaviors can help improve plan selection support.

Keywords:
Real-world decisionsaging decision makerchoice complexitychoice overloadolder adults

Related Experiment Videos

Area of Science:

  • Behavioral economics
  • Health services research
  • Decision science

Background:

  • The Medicare Part D program offers stand-alone prescription drug insurance to US residents aged 65 and older, plus those with disabilities.
  • Beneficiaries annually choose between staying with their current plan or switching to alternatives.
  • Complex choices in Medicare Part D plan selection are informed by behavioral decision-making research.

Purpose of the Study:

  • To understand Medicare Part D beneficiaries' real-world experiences in making annual plan choices.
  • To examine the strategies employed by beneficiaries who stayed with their initial plan versus those who switched.

Main Methods:

  • Phone interviews were conducted in July 2023 with 20 Medicare Part D beneficiaries (aged 57-86).
  • Participants were recruited via the US-wide Understanding America Study.
  • Qualitative analysis focused on decision-making strategies and experiences.

Main Results:

  • Both "stayers" (11) and "switchers" (9) used similar strategies with varied success.
  • Decision-support tools (e.g., Medicare plan-finder) were often time-consuming and confusing.
  • Beneficiaries relied on advice from brokers, agents, and pharmacists, sometimes without critical evaluation.
  • Information processing varied, with some using heuristics and others considering limited options.
  • Annual plan comparisons were infrequent, and some beneficiaries delayed choices despite plan changes or negative experiences due to time and knowledge constraints.

Conclusions:

  • Medicare beneficiaries utilize strategies identified in behavioral decision-making research for Medicare Part D plan choices.
  • Each strategy presented unique challenges, impacting the effectiveness of plan selection.
  • Policy recommendations are suggested to better assist beneficiaries in navigating their Medicare Part D plan choices.